Literature DB >> 7776445

Expression of nm23 in cell lines derived from patients with metastatic renal cell carcinoma.

M M Walther1, P Anglard, J Gnarra, R Pozzatti, D Venzon, A de la Rosa, N J MacDonald, P S Steeg, W M Linehan.   

Abstract

Reduced expression of nm23 has been associated with increased metastases and decreased survival in a variety of malignancies. In the present study, the expression of nm23 was examined by Northern and Western blot analyses in a series of cell lines derived from patients with metastatic renal cell carcinoma. Two of twelve (17%) informative cell lines derived from 9 patients had loss of heterozygosity at Nm23-H1. Twenty-two renal cancer cell lines derived from primary tumors, 5 cell lines derived from metastatic tumors and 4 short-term cultures of normal proximal renal tubular cells all expressed Nm23 mRNA in varying amounts. On average, the level of expression of Nm23 mRNA in short-term cultures of benign proximal renal tubular cells was found to be similar to the level seen in renal cancer cell lines. Twenty-eight cell lines derived from renal primary tumors and 8 cell lines derived from metastatic tumors expressed both the Nm23-H1 and Nm23-H2 proteins. High or low relative expression of nm23 at the mRNA or protein level did not correlate with survival. The absence of any anomalous pattern of expression of the nm23 genes and the lack of correlation of expression with survival suggests that nm23 does not play a central role in the progression of this tumor type.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776445

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  Loss of heterozygosity of the nm23-H1 gene in human renal cell carcinomas.

Authors:  M H Bosnar; K Pavelić; R Hrasćan; Z Zeljko; I Krhen; Z Marekoyic; S Krizanac; J Pavelíc
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  Regulation of the metastasis suppressor Nm23-H1 by tumor viruses.

Authors:  Shuvomoy Banerjee; Hem Chandra Jha; Erle S Robertson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-10       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.